World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
24379
World Ranking
16638
National Ranking
873

Alfred Reiter publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alfred Reiter sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 235 publications — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Alfred Reiter D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alfred Reiter sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 81 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Alfred Reiter is affiliated with the University of Giessen in Germany and focuses their research primarily within the field of medicine. Their work spans several specialized subfields, including pathology and forensic medicine, neurology, oncology, public health, environmental and occupational health, and pulmonary and respiratory medicine.

The scientist's main research topics cover an array of areas related to cancer and hematologic diseases, specifically:

  • Lymphoma Diagnosis and Treatment
  • CNS Lymphoma Diagnosis and Treatment
  • Acute Lymphoblastic Leukemia research
  • Sarcoma Diagnosis and Treatment
  • Viral-associated cancers and disorders
  • CAR-T cell therapy research
  • Childhood Cancer Survivors' Quality of Life

Reiter's recent published papers illustrate their contribution to pediatric oncology and lymphoma treatment research. Notable works include:

  • "Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial" (2020) published in Cancers
  • "Progressive or Relapsed Burkitt Lymphoma or Leukemia in Children and Adolescents after BFM-type First-line Therapy" (2020) published in Blood
  • "Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial" (2020) published in Journal of Clinical Oncology
  • "Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group" (2020) published in Haematologica
  • "Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma" (2023) published in The Lancet Haematology

Their frequent coauthors indicate collaboration across multiple studies, including:

  • Andishe Attarbaschi
  • Wilhelm Woessmann
  • Birgit Burkhardt
  • Wolfram Klapper
  • Grażyna Wróbel

The regular publication venues in which Reiter's work appears are diverse but focused on hematology and oncology-oriented journals, including:

  • Cancers
  • Blood
  • Journal of Clinical Oncology
  • Haematologica
  • The Lancet Haematology

The research represents a sustained engagement with pediatric lymphomas and related malignancies, examining diagnostic, therapeutic, and long-term survivor outcomes. Their work also intersects with broader public health concerns and neurological aspects within oncology research. No record of book publications or awards is currently noted in their profile.

Best Publications

  • Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.

    Martin Schrappe;Alfred Reiter;Wolf-Dieter Ludwig;Jochen Harbott

  • Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86

    A Reiter;M Schrappe;WD Ludwig;W Hiddemann

  • Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

    Anja Möricke;Alfred Reiter;Martin Zimmermann;Helmut Gadner

  • Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

    M Schrappe;A Reiter;M Zimmermann;J Harbott

  • Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000

    A Möricke;M Zimmermann;A Reiter;G Henze

  • Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.

    Mitchell S. Cairo;Bertrand Coiffier;Alfred Reiter;Anas Younes

  • Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.

    Alfred Reiter;Martin Schrappe;Markus Tiemann;Wolf-Dieter Ludwig

  • Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

    Martin Schrappe;Maria Grazia Valsecchi;Claus R. Bartram;André Schrauder

  • Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.

    Michael Dördelmann;Alfred Reiter;Arndt Borkhardt;Wolf-Dieter Ludwig

  • Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.

    Alfred Reiter;Martin Schrappe;Wolf-Dieter Ludwig;Markus Tiemann

  • The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95

    Wilhelm Woessmann;Kathrin Seidemann;Georg Mann;Martin Zimmermann

  • Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.

    A Reiter;M Schrappe;R Parwaresch;G Henze

  • Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia.

    Karl Welte;Cornelia Zeidler;Alfred Reiter;Wolfgang Müller

  • Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.

    Kathrin Seidemann;Markus Tiemann;Martin Schrappe;Elif Yakisan

  • The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence.

    Birgit Burkhardt;Martin Zimmermann;Ilske Oschlies;Felix Niggli

  • Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy.

    Lutz Löning;Martin Zimmermann;Alfred Reiter;Peter Kaatsch

  • Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction.

    J. Maurer;E. Thiel;W.-D. Ludwig;J.W.G. Janssen

  • Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.

    Ursula Creutzig;M. Zimmermann;J. Ritter;D. Reinhardt

  • High Cure Rates and Reduced Long-Term Toxicity in Pediatric Hodgkin's Disease: The German-Austrian Multicenter Trial DAL-HD-90

    Günther Schellong;Richard Pötter;Jürgen Brämswig;Wolfgang Wagner

  • Diagnostic Cerebrospinal Fluid Examination in Children With Acute Lymphoblastic Leukemia: Significance of Low Leukocyte Counts With Blasts or Traumatic Lumbar Puncture

    Britta Bürger;Martin Zimmermann;Georg Mann;Joachim Kühl

Frequent Co-Authors

Martin Zimmermann
Martin Zimmermann Hannover Medical School
Martin Schrappe
Martin Schrappe Kiel University
Helmut Gadner
Helmut Gadner St Anna Children's Hospital
Wolfram Klapper
Wolfram Klapper Kiel University
Karl Welte
Karl Welte University of Tübingen
Günter Henze
Günter Henze Charité - University Medicine Berlin
Jochen Harbott
Jochen Harbott University of Giessen
Laurence Brugières
Laurence Brugières Institut Gustave Roussy
Charlotte M. Niemeyer
Charlotte M. Niemeyer University of Freiburg
Martin Stanulla
Martin Stanulla Hannover Medical School

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine but seeking flexible pathways, a variety of adn to fnp bridge programs allow registered nurses with an associate degree to advance their education and become family nurse practitioners. These programs are typically tailored to working nurses and can be pursued online.

If you have an interest in preventive care or community health, earning an online bachelor's in nutrition can open doors to roles in wellness, education, and specialized clinical settings. This degree is suitable for those passionate about promoting healthy lifestyles.

For those leaning towards healthcare leadership, consider online mha programs cahme accredited. These programs provide advanced training in healthcare administration, preparing graduates for management and executive positions in hospitals and public health organizations.

Finally, online rn to bsn programs without clinical requirements are an excellent way for nurses to earn a bachelor's degree without additional in-person responsibilities. Whether you aim for direct patient care or a leadership track, these flexible online options can help you advance your medical career.

Best Scientists Citing Alfred Reiter

Trending Scientists

Recently Published Articles